卡培他滨联合贝伐珠单抗维持治疗对比观察在转移性结直肠癌中的更新结果及分子亚组分析:CAIRO3 III期研究
CAIRO3 III期研究的事后分析纳入558例转移性结直肠癌患者,比较CAP-B维持治疗与观察的疗效。中位随访87个月,所有突变亚组均显示PFS2显著改善,RAS/BRAF野生型和V600EBRAF突变型获益最明显。
要点
- CAP-B维持治疗在RAS/BRAF野生型、RAS突变型及V600EBRAF突变型亚组均显著改善PFS2。
- RAS/BRAF野生型HR 0.57,RAS突变型HR 0.74,V600EBRAF突变型HR 0.28。
- RAS突变亚组总生存未见显著获益,其余亚组次要终点均显著改善。
核心结论
- CAP-B维持治疗在mCRC一线治疗中跨所有突变亚组有效,RAS/BRAF野生型和V600EBRAF突变型患者获益最明显。
研究设计与样本
- III期CAIRO3研究的事后分析,558例既往未治疗mCRC患者经6周期CAPOX-B诱导后随机接受CAP-B维持治疗(n=279)或观察(n=279)。
- 主要终点为首次进展后CAPOX-B再引入至第二次进展的PFS2,中位随访87个月(IQR 69-97)。
- 集中评估RAS/BRAF突变状态和MMR状态,无法集中评估时使用本地结果。
主要发现
- RAS突变240/420(58%),BRAF突变36/381(9%),MMR缺陷4/279(1%)。
- RAS/BRAF野生型PFS2 HR 0.57(95%CI 0.39-0.84),RAS突变型HR 0.74(95%CI 0.55-0.98),V600EBRAF突变型HR 0.28(95%CI 0.12-0.64)。
- 除RAS突变亚组总生存外,所有突变亚组次要终点均显著改善。
- 右侧肿瘤预后较差,但左右侧肿瘤患者均从维持治疗中显著获益。
临床怎么用
- 6周期CAPOX-B诱导后,CAP-B维持治疗可作为mCRC一线治疗策略,跨突变亚组均有效。
- RAS/BRAF野生型和V600EBRAF突变型患者维持治疗获益最明显。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients is effective, without compromising quality of life. In this post hoc analysis with updated follow-up and data regarding sidedness, we defined subgroups according to RAS/BRAF mutation status and mismatch repair (MMR) status, and investigated their influence on treatment efficacy. PATIENTS AND METHODS: A total of 558 patients with previously untreated mCRC and stable disease or better after six cycles CAPOX-B induction treatment were randomised to either CAP-B maintenance treatment (n = 279) or observation (n = 279). Upon first progression, patients were to receive CAPOX-B reintroduction until second progression (PFS2, primary end point). We centrally assessed RAS/BRAF mutation status and MMR status, or used local results if central assessment was not possible. Intention-to-treat stratified Cox models adjusted for baseline covariables were used to examine whether treatment efficacy was modified by RAS/BRAF mutation status. RESULTS: RAS, BRAF mutations, and MMR deficiency were detected in 240/420 (58%), 36/381 (9%), and 4/279 (1%) patients, respectively. At a median follow-up of 87 months (IQR 69-97), all mutational subgroups showed significant improvement from maintenance treatment for the primary end point PFS2 [RAS/BRAF wild-type: hazard ratio (HR) 0.57 (95% CI 0.39-0.84); RAS-mutant: HR 0.74 (0.55-0.98); V600EBRAF-mutant: HR 0.28 (0.12-0.64)] and secondary end points, except for the RAS-mutant subgroup regarding overall survival. Adjustment for sidedness instead of primary tumour location yielded comparable results. Although right-sided tumours were associated with inferior prognosis, both patients with right- and left-sided tumours showed significant benefit from maintenance treatment. CONCLUSIONS: CAP-B maintenance treatment after six cycles CAPOX-B is effective in first-line treatment of mCRC across all mutational subgroups. The benefit of maintenance treatment was most pronounced in patients with RAS/BRAF wild-type and V600EBRAF-mutant tumours. CLINICALTRIALS.GOV NUMBER: NCT00442637.
引用
- Goey KKH, Elias SG, van Tinteren H, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017. PMID: 28911067. doi:10.1093/annonc/mdx322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。